Cancer risk from cardiac CT overstated
Synerx Pharma, LLC has announced the submission to the FDA of Isosulfan Blue Injection (generic equivalent to Lymphazurin, Covidien (formerly US Surgical)). This ANDA submission is the culmination of a four year joint effort by Synerx Pharma, LLC and its exclusive raw material supplier Apicore, LLC. According to Synerx Pharma and Apicore, the active ingredient
Full Post: Synerx Pharma announces FDA submission of Isosulfan Blue injection ANDA
Radiology and cardiovascular researchers from the Medical University of South Carolina in Charleston, S.C., today presented new data that shows the risk of cancer from exposure to radiation during computed tomography for cardiovascular disease has been overstated and that new estimates are several times lower than previously published conclusions.
The MUSC researchers presented their findings at the American Heart Association’s meeting in New Orleans.
In previously published studies, different researchers concluded the risk of cancer from radiation exposure during CT for cardiovascular disease was approximately 1 in 114, but the new study suggests the risk is 1 in 1000.
U. Joseph Schoepf, MD, and colleagues from MUSC, claim previous studies assessing lifetime risks of cancer from radiation in cardiac CT are based on unreliable models of patients who undergo CT for cardiovascular disease.
In conducting his study, Scheopf studied 104 consecutive patients undergoing 64-slice cardiac CT at the Medical University of South Carolina. The majority of the patients were male with median age of 59 and median weight of 202 pounds. The research team converted organ radiation doses into risk using a previously published and validated measure. Patient cancer risks were adjusted taking into account patient sex, age and weight, the latter being an often neglected factor influencing radiation risk.
The new risk in this patient population, which mirrors more closley the typical patients who receive cardiac CT, was 1 in 1000, Scheopf said.
“Thus, in a real-life clinical patient group, the realistic risk of radiation induced cancer from cardiac CT is substantially lower than previously reported for general populations,” Scheopf said.
He added that radiation exposure is a serious issue and patients need to talk to their doctors before undergoing any tests that exposes them to radiation to ensure the test is appropriate and the patient fits under patient selection guidelines published by the American Heart Association and the American College of Radiology.
Do the biological underpinnings of heart failure share more in common with cancerous tumors than other cardiovascular diseases? Research presented at American Heart Association meeting may show why heart failure treatments fail. A team of Medical University of South Carolina (MUSC) researchers and cardiologists are presenting a number of studies at the American Heart Association
Full Post: Research shows why some heart failure treatments fail
A novel angled gantry approach to coronary CT angiography reduced radiation exposure to the breast by more than 50%, according to Thomas Jefferson University researchers. Ethan Halpern, M.D., associate professor of Radiology at Jefferson Medical College of Thomas Jefferson University in Philadelphia, presented the research at the 94th Scientific Assembly and Annual Meeting of the
Full Post: Novel angled gantry approach reduces breast radiation exposure
Breast cancer patients who receive breast-conserving therapy and radiation do not need a follow-up mammogram until 12 months after radiation, despite current guidelines that recommend follow-up mammograms at between six and 12 months after radiation, according to a November 15 study in the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society
Full Post: Mammogram most effective 12 months after radiation
In a first of its kind study, a first-degree family history of prostate cancer has no impact on the treatment outcomes of prostate cancer patients treated with brachytherapy (also called seed implants), and patients with this type of family history have clinical and pathologic characteristics similar to men with no family history at all, according
Full Post: First-degree family history of prostate cancer does not affect some treatment outcomes
Despite substantial progress in the diagnosis and treatment of heart attack patients, prevention of recurrent heart attacks continues to be a major clinical challenge. A new study showed that patients who suffered a non-fatal heart attack within the first three months of hospitalization for chest pain had a significantly higher risk for dying or having
Full Post: Heart attack prevention within three months after hospitalization significantly averted future attacks